OrthoLogic Corporation Announces Initiation of Dosing for Second AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring

July 10, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

TEMPE, Ariz., July 9, 2008 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the initiation of dosing for its second AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 1